IMVIONIX Acquires U.S. and Canadian Rights to BEOVU® (brolucizumab-dbll), Marking the Company's Official Launch
Acquisition of FDA-Approved Retinal Therapy Signals IMVIONIX's Entry as a Commercial-Stage Ophthalmology Company PEACHTREE CORNERS, Ga., Nov. 10, 2026 — IMVIONIX Inc., a privately held biotechnology company dedicated to advancing the delivery of retinal…











